Wang R, Song Y, Yan Y, Ding Z. Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: A meta-analysis. Atherosclerosis. 2016;254:193–9.

Article  CAS  PubMed  Google Scholar 

Zuo T, Liu X, Jiang L, Mao S, Yin X, Guo L. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc Disord. 2016;16(1):207.

Article  PubMed  PubMed Central  Google Scholar 

Saito Y, Nakayama T, Sugimoto K, Fujimoto Y, Kobayashi Y. Relation of lipid content of coronary plaque to level of serum uric acid. Am J Cardiol. 2015;116(9):1346–50.

Article  CAS  PubMed  Google Scholar 

Si K, Wei C, Xu L, Zhou Y, Lv W, Dong B, et al. Hyperuricemia and the risk of heart failure: pathophysiology and therapeutic implications. Front Endocrinol. 2021;12:770815.

Article  Google Scholar 

Kawasoe S, Kubozono T, Yoshifuku S, Ojima S, Oketani N, Miyata M, et al. Uric acid level and prevalence of atrial fibrillation in a Japanese general population of 285,882. Circ J. 2016;80(12):2453–9.

Article  PubMed  Google Scholar 

Tamariz L, Hernandez F, Bush A, Palacio A, Hare JM. Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm. 2014;11(7):1102–8.

Article  PubMed  Google Scholar 

Tsai K-Z, Chu C-C, Huang W-C, Sui X, Lavie CJ, Lin G-M. Prediction of various insulin resistance indices for the risk of hypertension among military young adults: the CHIEF cohort study, 2014–2020. Cardiovasc Diabetol. 2024;23(1):141.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009;61(2):225–32.

Article  CAS  PubMed  Google Scholar 

Niskanen LK, Laaksonen DE, Nyyssönen K, Alfthan G, Lakka HM, Lakka TA, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164(14):1546–51.

Article  CAS  PubMed  Google Scholar 

Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000;283(18):2404–10.

Article  CAS  PubMed  Google Scholar 

Zhao G, Huang L, Song M, Song Y. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis. 2013;231(1):61–8.

Article  CAS  PubMed  Google Scholar 

Quesada A, Quesada-Ocete J, Quesada-Ocete B, González-Ritonnale A, Marcaida-Benito G, Moral- Ronda VD, et al. Long-term hyperuricemia impact on atrial fibrillation outcomes. Curr Probl Cardiol. 2024;49(7):102608.

Article  PubMed  Google Scholar 

Saito Y, Tanaka A, Node K, Kobayashi Y. Uric acid and cardiovascular disease: A clinical review. J Cardiol. 2021;78(1):51–7.

Article  PubMed  Google Scholar 

Tsai K-Z, Liu P-Y, Huang W-C, Lima JAC, Lavie CJ, Lin G-M. Sex-specific cardiometabolic risk markers of left ventricular mass in physically active young adults: the CHIEF heart study. Sci Rep. 2022;12(1):11536.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham heart study. Ann Intern Med. 1999;131(1):7–13.

Article  CAS  PubMed  Google Scholar 

Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, et al. Impact of oxypurinol in patients with symptomatic heart failure Results of the OPT-CHF study. J Am Coll Cardiol. 2008;51(24):2301–9.

Article  CAS  PubMed  Google Scholar 

Nasr G, Maurice C. Allopurinol and global left myocardial function in heart failure patients. J Cardiovasc Dis Res. 2010;1(4):191–5.

Article  PubMed  PubMed Central  Google Scholar 

Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation. 2015;131(20):1763–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012;60(5):1148–56.

Article  CAS  PubMed  Google Scholar 

Segal MS, Srinivas TR, Mohandas R, Shuster JJ, Wen X, Whidden E, et al. The effect of the addition of allopurinol on blood pressure control in African Americans treated with a thiazide-like diuretic. J Am Soc Hypertens. 2015;9(8):610-9.e1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gunawardhana L, McLean L, Punzi HA, Hunt B, Palmer RN, Whelton A, et al. Effect of febuxostat on ambulatory blood pressure in subjects with hyperuricemia and hypertension: a phase 2 randomized placebo-controlled study. J Am Heart Assoc. 2017;6(11):e006683.

Article  PubMed  PubMed Central  Google Scholar 

Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375(9732):2161–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105(22):2619–24.

Article  CAS  PubMed  Google Scholar 

Sakabe M, Fujiki A, Sakamoto T, Nakatani Y, Mizumaki K, Inoue H. Xanthine oxidase inhibition prevents atrial fibrillation in a canine model of atrial pacing-induced left ventricular dysfunction. J Cardiovasc Electrophysiol. 2012;23(10):1130–5.

Article  PubMed  Google Scholar 

Xu X, Hu X, Lu Z, Zhang P, Zhao L, Wessale JL, et al. Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J Card Fail. 2008;14(9):746–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Q, Wang Z, Zhou J, Chen Z, Li Y, Li S, et al. Effect of urate-lowering therapy on cardiovascular and kidney outcomes: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2020;15(11):1576–86.

Article  PubMed  PubMed Central  Google Scholar 

Zhang T, Pope JE. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis. Rheumatology. 2017;56(7):1144–53.

Article  CAS  PubMed  Google Scholar 

FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744–60.

Article  PubMed  Google Scholar 

Givertz MM. Treating gout in patients with cardiovascular disease. J Am Coll Cardiol. 2018;71(9):1005–8.

Article  PubMed